GARDP, Eisai and Takeda Announce Partnership in the Search for New Antibiotics

GARDP 、卫材和武田制药宣布合作,将共同致力于新抗生素的研究和开发

2018-12-12 15:19:56 WALLSTREET_HealthNews

本文共1030个字,阅读需3分钟

First multi-actor partnership tests chemical compounds for antibacterial activity The Global Antibiotic Research and Development Partnership (GARDP), Eisai Co., Ltd. and Takeda Pharmaceutical Company Limited (TSE: 4502) have signed an agreement for GARDP to access and screen components of Eisai and Takeda's chemical libraries. Both libraries will be tested by the Institut Pasteur Korea in the hope of discovering novel compounds with antibacterial activity. This multi- partner agreement supports GARDP's efforts to tackle serious bacterial infections by developing antibiotics while endeavouring to ensure their sustainable access. With few antibiotics in development, antimicrobial resistance is a major and rapidly growing global public health concern. Around 700,000 people die of drug-resistant infections every year.(1) Serious bacterial infections, and in particular Gram-negative bacterial infections, have been identified by the World Health Organization (WHO) as a global public health priority. The compounds that will be screened have emerged from Eisai and Takeda's latest medicinal chemistry efforts and have never been screened for antibacterial activity. They will be tested against bacteria identified as a critical priority for research and development of new antibiotics in WHO's global priority pathogen list.(2) Through this screening, GARDP seeks to identify novel compounds suitable for further optimization and development. "GARDP is very excited about this partnership. Not only can partnerships like this accelerate the discovery of new antibiotics, they can also support the pharmaceutical sector in staying engaged in antibiotic R&D," said Dr. Seamus O'Brien, Research and Development Director at GARDP. "Overcoming antibacterial resistance is key to achieve universal health coverage. GARDP's approach allows us to develop a drug from early exploratory to preclinical and clinical studies all the way to patients." "Eisai strongly identifies with GARDP's efforts to discover novel antibiotics to treat drug-resistant bacterial infections which have become a threat to human beings and are pleased to provide our compound library for screening. We sincerely hope new medicines will be discovered through this partnership to realize a world in which lives are no longer lost to drug-resistant bacteria," said Dr. Kappei Tsukahara, Senior Group Officer, Head of Human Health Care Data Creation Center, Head of Tsukuba Research Laboratories at Eisai. "Takeda is delighted to contribute to this creative partnership and extend our commitment to promoting the discovery of novel treatments to treat life-threatening antibiotic resistance," said Dr. Ceri Davies, Head of the Neuroscience Drug Discovery Unit at Takeda. "We are honoured to collaborate with GARDP on a global project of great importance to find a solution for antibiotic resistance. The world needs global cooperative action to prevent the post-antibiotic era. This work, instigated by GARDP, is an active response to this urgent global demand that connects Institut Pasteur Korea's resources with the technology of global pharmaceutical companies. We believe that together we can achieve much more," said Dr. Wangshick Ryu, CEO of the Institut Pasteur Korea.
第一个多演员伙伴关系测试化合物的抗菌活性 全球抗生素研究与开发合作伙伴关系(GARDP),Eisai Co.,Ltd。与武田制药有限公司(东京证券交易所股票代码:4502)已签署协议,允许GARDP访问和筛选组件Eisai和Takeda的化学图书馆。这两个库将由巴斯德研究所(Institut Pasteur Korea)进行测试,以期发现具有抗菌活性的新化合物。该多合作伙伴协议支持GARDP通过开发抗生素来解决严重细菌感染的努力,同时努力确保其可持续获取。 由于抗生素的开发很少,抗菌素耐药性是一个主要且快速增长的全球公共卫生问题。每年约有70万人死于抗药性感染。(1)世界卫生组织(WHO)已将严重的细菌感染,特别是革兰氏阴性细菌感染确定为全球公共卫生重点。 将要筛选的化合物来自Eisai和Takeda最新的药物化学研究,并且从未筛选过抗菌活性。他们将针对被确定为世界卫生组织全球优先病原体列表中新抗生素研究和开发的关键优先级进行测试。(2)通过此筛选,GARDP寻求鉴定适合进一步优化和开发的新化合物。 “GARDP对这种伙伴关系感到非常兴奋。这样的合作伙伴不仅可以加速新抗生素的发现,还可以支持制药行业继续从事抗生素研发,”研究与开发总监Seamus O'Brien博士说。 GARDP。 “克服抗菌药物抗性是实现全民健康覆盖的关键.GARDP的方法使我们能够开发从早期探索到临床前和临床研究一直到患者的药物。” “Eisai强烈认同GARDP努力发现新的抗生素来治疗对人类构成威胁的耐药性细菌感染,并很高兴为我们的化合物库提供筛查。我们真诚地希望通过这种伙伴关系发现新药物以实现一个生命不再因抗药性细菌而丧失的世界,“Eisai筑波研究实验室负责人,人类健康护理数据创建中心高级组长,Kappei Tsukahara博士说。 “武田很高兴为这种创造性的合作伙伴关系做出贡献,并致力于推动新型治疗方法的发现,以治疗威胁生命的抗生素耐药性,”武田神经科学药物发现部负责人Ceri Davies博士说。 “我们很荣幸能够与GARDP合作开展一个非常重要的全球项目,寻找抗生素耐药性的解决方案。世界需要采取全球合作行动来防止抗生素后期。这项工作由GARDP发起,是对此的积极回应。将巴斯德研究所的资源与全球制药公司的技术联系起来的紧急全球需求。我们相信,我们可以共同取得更多成就,“巴斯德研究所首席执行官Wangshick Ryu博士说。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文